Payment overview · 2025
General Payments
$143.76
8 reported records · 6 companies
Healthcare provider profile · identity verified
Debra A Durham, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PARKS, LA · NPI 1386646677
Verified facts
What the public records show
CMS Open Payments records show Debra A Durham, M.D. received $143.76 in general payments during 2025 across 8 reported records.
Lilly USA, LLC accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trintellix.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.00 | 25.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.04 | 23.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.23 | 14.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.16 | 14.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.52 | 12.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.81 | 11.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $143.76 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.04 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 176 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
176 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 578 | 103 |
| Montelukast Sodium | Montelukast Sodium | 553 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 86 |
| Gabapentin | Gabapentin | 374 | 80 |
| Metformin Hcl | Metformin Hcl | 350 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 62 |
| Losartan Potassium | Losartan Potassium | 229 | 51 |
| Tramadol Hcl | Tramadol Hcl | 222 | 48 |
| Buspirone Hcl | Buspirone Hcl | 207 | 38 |
| Omeprazole | Omeprazole | 193 | 38 |
| Trazodone Hcl | Trazodone Hcl | 189 | 33 |
| Jardiance | Empagliflozin | 176 | 26 |
| Mirtazapine | Mirtazapine | 174 | 34 |
| Allopurinol | Allopurinol | 172 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 43 |
| Lisinopril | Lisinopril | 163 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 26 |
| Potassium Chloride | Potassium Chloride | 158 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 36 |
| Lovastatin | Lovastatin | 148 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 141 | 25 |
| Glimepiride | Glimepiride | 138 | 25 |
| Ozempic | Semaglutide | 132 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 117 | 25 |
| Sertraline Hcl | Sertraline Hcl | 117 | 22 |
| Carvedilol | Carvedilol | 115 | 25 |
| Alprazolam | Alprazolam | 107 | 19 |
| Meloxicam | Meloxicam | 104 | 22 |
| Famotidine | Famotidine | 102 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 90 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 15 |
| Alendronate Sodium | Alendronate Sodium | 82 | 18 |
| Baclofen | Baclofen | 82 | 26 |
| Furosemide | Furosemide | 82 | 24 |
| Prednisone | Prednisone | 80 | 26 |
| Simvastatin | Simvastatin | 79 | 16 |
| Xarelto | Rivaroxaban | 72 | suppressed |
| Valsartan | Valsartan | 71 | 19 |
| Meclizine Hcl | Meclizine Hcl | 66 | 18 |
| Azithromycin | Azithromycin | 64 | 56 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 14 |
| Donepezil Hcl | Donepezil Hcl | 62 | 13 |
| Euthyrox | Levothyroxine Sodium | 62 | suppressed |
| Lactulose | Lactulose | 62 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Mupirocin | Mupirocin | 61 | 39 |
| Eliquis | Apixaban | 60 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 11 |
| Metformin Hcl Er | Metformin Hcl | 55 | suppressed |
| Sucralfate | Sucralfate | 55 | 16 |
| Celecoxib | Celecoxib | 52 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 12 |
| Nabumetone | Nabumetone | 52 | suppressed |
| Linzess | Linaclotide | 51 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 49 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 12 |
| Irbesartan | Irbesartan | 49 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 48 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 40 |
| Azelastine Hcl | Azelastine Hcl | 46 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 12 |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Fluconazole | Fluconazole | 43 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 11 |
| Colchicine | Colchicine | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Spironolactone | Spironolactone | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 31 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 39 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 32 |
| Finasteride | Finasteride | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 13 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 35 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 13 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Cefadroxil | Cefadroxil | 32 | 26 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Haloperidol | Haloperidol | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 25 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 19 |
| Ketoconazole | Ketoconazole | 22 | 12 |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $143.76 · 8 records | Lilly USA, LLC | Cologuard Collection Kit, IBSRELA, JARDIANCE, NEXLETOL, TRINTELLIX, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error